Cell and gene therapies rely on speed for success. Yet the downstream signaling associated with living therapies present additional complexities to explore. You need the right technology and novel clinical tools to reduce time from bench to bedside.

You need to build the right infrastructure and capabilities into the clinical process to support your product’s commercialization. A supply chain strategy will help you move from research-based processes to commercial automation that meets demand.

Today fewer than 25% of eligible patients benefit from cell and gene therapies. Expanding the impact of these therapies must start early in their development as you plan your network strategy and design flexible contracts with clinical trial sites. 

Architecting a connected cell and gene therapy organization is critical, whether your goal is to stand alone or with another business. Building this structure starts with defining roles and acquiring talent, then establishing an effective commercial model.

We help you bring artificial intelligence (AI) to your processes. Taking a systems biology approach to research, we leverage in silico technology to improve target identification and expedite the time from identification to clinical trials.

We work with you to establish a scalable infrastructure across your commercial, supply chain and operations functions to drive more-integrated decision-making across the value chain, leading to a differentiated customer experience. 

For therapies that challenge traditional payment options, we help design better outcome-based, risk sharing models while communicating their value to payers and providers. We help you build new partnerships to deliver the promise of curing more patients.  

Organizations must introduce new ways of exchanging information. Cell and gene therapies depend on connected data from R&D, CMC and commercial to deliver at the service levels and product engineering required for these platform-based businesses.